Copyright
©The Author(s) 2022.
World J Hepatol. Feb 27, 2022; 14(2): 429-441
Published online Feb 27, 2022. doi: 10.4254/wjh.v14.i2.429
Published online Feb 27, 2022. doi: 10.4254/wjh.v14.i2.429
Figure 2 The statistical analysis subsequently focused on β-Arr-2 expression in the gastric antrum.
A: Comparison between nonselective β-blockers (NSBB) responders and non-responders as regards β-Arrestin-2 expression, aP < 0.001; bP = 0.23; cP = 0.40; B: The frequency of small, medium, and large esophageal varices according to different intensities of β-Arrestin-2 expression at baseline; C: Comparison between NSBB responders and Non-responders as regards the changes in the frequency of low, medium, and large esophageal varices before and after treatment; D: Comparison between NSBB responders and Non-responders as regards the changes in the frequency of low, moderate, and strong antral β-Arrestin-2 expression before and after treatment. EV: Esophageal varices; NSBB: Nonselective beta-blockers.
- Citation: Lashen SA, Shamseya MM, Madkour MA, Abdel Salam RM, Mostafa SS. β-arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: A prospective study. World J Hepatol 2022; 14(2): 429-441
- URL: https://www.wjgnet.com/1948-5182/full/v14/i2/429.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i2.429